JP2017522292A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522292A5
JP2017522292A5 JP2016574898A JP2016574898A JP2017522292A5 JP 2017522292 A5 JP2017522292 A5 JP 2017522292A5 JP 2016574898 A JP2016574898 A JP 2016574898A JP 2016574898 A JP2016574898 A JP 2016574898A JP 2017522292 A5 JP2017522292 A5 JP 2017522292A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
less
composition according
ophthalmic
muscarinic antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016574898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522292A (ja
JP6678362B2 (ja
Filing date
Publication date
Priority claimed from US14/726,139 external-priority patent/US9421199B2/en
Application filed filed Critical
Publication of JP2017522292A publication Critical patent/JP2017522292A/ja
Publication of JP2017522292A5 publication Critical patent/JP2017522292A5/ja
Priority to JP2020014108A priority Critical patent/JP7505888B2/ja
Application granted granted Critical
Publication of JP6678362B2 publication Critical patent/JP6678362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016574898A 2014-06-24 2015-06-23 眼科用組成物 Active JP6678362B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020014108A JP7505888B2 (ja) 2014-06-24 2020-01-30 眼科用組成物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US62/016,502 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US62/096,433 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US62/151,926 2015-04-23
US14/726,139 2015-05-29
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020014108A Division JP7505888B2 (ja) 2014-06-24 2020-01-30 眼科用組成物

Publications (3)

Publication Number Publication Date
JP2017522292A JP2017522292A (ja) 2017-08-10
JP2017522292A5 true JP2017522292A5 (enExample) 2018-08-09
JP6678362B2 JP6678362B2 (ja) 2020-04-08

Family

ID=54868660

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016574898A Active JP6678362B2 (ja) 2014-06-24 2015-06-23 眼科用組成物
JP2020014108A Active JP7505888B2 (ja) 2014-06-24 2020-01-30 眼科用組成物
JP2022003408A Pending JP2022062045A (ja) 2014-06-24 2022-01-12 眼科用組成物
JP2023180519A Pending JP2024050526A (ja) 2014-06-24 2023-10-19 眼科用組成物
JP2025080139A Pending JP2025131595A (ja) 2014-06-24 2025-05-12 眼科用組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020014108A Active JP7505888B2 (ja) 2014-06-24 2020-01-30 眼科用組成物
JP2022003408A Pending JP2022062045A (ja) 2014-06-24 2022-01-12 眼科用組成物
JP2023180519A Pending JP2024050526A (ja) 2014-06-24 2023-10-19 眼科用組成物
JP2025080139A Pending JP2025131595A (ja) 2014-06-24 2025-05-12 眼科用組成物

Country Status (22)

Country Link
US (12) US9421199B2 (enExample)
EP (3) EP4115884A1 (enExample)
JP (5) JP6678362B2 (enExample)
KR (4) KR102506109B1 (enExample)
CN (3) CN110638749A (enExample)
BR (1) BR112016030368B1 (enExample)
CA (1) CA2953363C (enExample)
DK (1) DK3160471T3 (enExample)
ES (1) ES2924243T3 (enExample)
FI (1) FIC20250034I1 (enExample)
HR (1) HRP20220972T1 (enExample)
HU (1) HUE059521T2 (enExample)
IL (1) IL249643B (enExample)
LT (1) LT3160471T (enExample)
PL (1) PL3160471T3 (enExample)
PT (1) PT3160471T (enExample)
RS (1) RS63486B1 (enExample)
SG (3) SG10201707617VA (enExample)
SI (1) SI3160471T1 (enExample)
SM (1) SMT202200447T1 (enExample)
TW (4) TWI855319B (enExample)
WO (1) WO2015200361A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201809822SA (en) * 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
WO2018154440A1 (en) * 2017-02-21 2018-08-30 Singapore Health Services Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
KR102633606B1 (ko) * 2017-03-23 2024-02-02 싱가포르 헬스 서비시즈 피티이 엘티디 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제
KR102535910B1 (ko) 2017-03-27 2023-05-25 리제너론 파아마슈티컬스, 인크. 살균 방법
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
KR102654048B1 (ko) 2017-07-20 2024-04-03 세인다 파마슈티컬 광저우 코포레이션 근시 치료용 조성물 및 방법
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
KR20250109788A (ko) 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
CN109157503B (zh) * 2018-09-25 2019-08-16 沈阳兴齐眼药股份有限公司 防治nitm的药物组合物及其医药用途
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
SG11202108457UA (en) * 2019-02-06 2021-09-29 Tearclear Corp Systems and methods for preservative removal from ophthalmic formulations comprising complexing agents
EP3701938B8 (en) 2019-03-01 2024-02-21 Medivis S.R.L. Ophthalmic formulations based on atropine
WO2020198344A1 (en) * 2019-03-26 2020-10-01 Aura Biosciences, Inc. Human papillomavirus nanoparticle formulations
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
US20220288114A1 (en) * 2019-07-11 2022-09-15 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
WO2021141672A2 (en) * 2019-11-15 2021-07-15 Silk Technologies, Ltd. Stable formulations of silk-derived protein
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
JP2023505841A (ja) * 2019-12-16 2023-02-13 シドネキシス,インク. D2oを含む眼科用組成物
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
WO2022026796A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
JP2024505517A (ja) * 2021-01-28 2024-02-06 グラウコス コーポレイション 製剤
AU2022217160A1 (en) 2021-02-03 2023-08-17 Ads Therapeutics Llc Topical ophthalmological compositions
CA3205883A1 (en) * 2021-02-04 2022-08-11 Gregory I. Ostrow Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
EP4308080A4 (en) * 2021-03-16 2025-02-26 Vyluma Inc. MULTI-DOSE CONTAINERS FOR OPHTHALMIC COMPOSITIONS
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
US12310474B2 (en) 2021-10-08 2025-05-27 Johnson & Johnson Vision Care, Inc. Multi-material lens package
WO2023081891A2 (en) * 2021-11-05 2023-05-11 Calm Water Therapeutics Llc Methods for using bioadhesive and steric interactions of copolymers with at least two moieties to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
WO2023215407A2 (en) * 2022-05-03 2023-11-09 Iview Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
JP2025528009A (ja) 2022-07-15 2025-08-26 ドーシ,プラフル 医薬品と薬剤などの不安定な構成要素の安定剤とを含むコンタクトレンズを作製及び使用する方法
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
WO2024192323A2 (en) * 2023-03-16 2024-09-19 Glaukos Corporation Ophthalmic cream formulations and their uses
TW202525288A (zh) * 2023-10-26 2025-07-01 英商庫博光學國際有限公司 液體組合物

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
BE624258A (enExample) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
AU7528696A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
JP2000509971A (ja) 1996-04-10 2000-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 化学的シャペローンを用いる遺伝的欠陥の修正
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
EP1206283A2 (en) 1999-05-17 2002-05-22 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
JP5000835B2 (ja) 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1397132A4 (en) 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
CA2535846A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ579516A (en) 2004-01-27 2011-01-28 Osteotech Inc Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
WO2006084275A2 (en) 2005-02-04 2006-08-10 Auburn University Contact drug delivery system
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
WO2007053747A2 (en) 2005-11-01 2007-05-10 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) * 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
EP2508189A3 (de) 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
EP2962682B1 (en) 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
EP2464387A4 (en) * 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
KR20130111932A (ko) * 2010-04-30 2013-10-11 세로스 메디컬, 엘엘씨 조합 방식을 이용하여 안구 조직을 치료하는 방법 및 장치
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
CA2805425C (en) 2010-07-15 2019-07-23 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
EP2593056B1 (en) 2010-07-15 2020-10-21 Eyenovia, Inc. Drop generating device
JP5823766B2 (ja) * 2010-07-30 2015-11-25 大塚製薬株式会社 医薬組成物
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
US20120225952A1 (en) 2011-03-03 2012-09-06 Warner Kevin S Non-aqueous silicone-based ophthalmic formulations
MX346312B (es) 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
MX360666B (es) 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
US20140350049A1 (en) 2011-11-29 2014-11-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
JP5345746B1 (ja) * 2012-02-27 2013-11-20 ロート製薬株式会社 眼科用組成物
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
WO2013167865A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
KR102168906B1 (ko) 2012-05-14 2020-10-22 아이노비아 인코포레이티드 층류 액적 생성기 디바이스 및 이용 방법들
SG11201407431RA (en) 2012-05-15 2014-12-30 Eyenovia Inc Ejector devices, methods, drivers, and circuits therefor
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
US20160018671A1 (en) 2013-03-29 2016-01-21 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
KR102027663B1 (ko) 2013-05-06 2019-10-01 가오슝 창 궁 메모리얼 하스피털 약학적 조성물 및 이의 용도
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
SG11201809822SA (en) 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2018154440A1 (en) 2017-02-21 2018-08-30 Singapore Health Services Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
KR102654048B1 (ko) 2017-07-20 2024-04-03 세인다 파마슈티컬 광저우 코포레이션 근시 치료용 조성물 및 방법
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
JP2023505841A (ja) 2019-12-16 2023-02-13 シドネキシス,インク. D2oを含む眼科用組成物

Similar Documents

Publication Publication Date Title
JP2017522292A5 (enExample)
Olivares et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)
JP2018521000A5 (enExample)
JP2013526572A5 (enExample)
CA3045733A1 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP2011520805A5 (enExample)
JP6968457B2 (ja) 選択された抗コリン作動性両性イオンの使用
RU2013121788A (ru) Ингибиторы репликации вич
HRP20220972T1 (hr) Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu
JP2016106150A5 (enExample)
JP2015025011A5 (enExample)
KR20190013877A (ko) 아트로핀-함유 수성 조성물
WO2016172712A3 (en) Ophthalmic composition
TWI832920B (zh) 抑制軟性隱形眼鏡變質之眼科用組成物
JP2011516477A5 (enExample)
JP2016512558A5 (enExample)
JP2014506927A5 (enExample)
RU2015144083A (ru) Комбинация лекарственных средств
JP2013525493A5 (enExample)
KR20180095928A (ko) 노안의 치료를 위한 조성물
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
JP2013500977A5 (enExample)
JP2013534527A5 (enExample)
RU2014148758A (ru) Офтальмологические композиции с улучшенной защитой от обезвоживания и удерживанием